These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 30246215

  • 1. Effect of levodopa on frontal-subcortical and posterior cortical functioning in patients with Parkinson's disease.
    Gul A, Yousaf J.
    Singapore Med J; 2019 Aug; 60(8):414-417. PubMed ID: 30246215
    [Abstract] [Full Text] [Related]

  • 2. Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms.
    Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Catania V, Nobili F, Arnaldi D, Famà F, Orzi F, Buttinelli C, Giubilei F, Bonanni L, Franciotti R, Onofrj M, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Fraioli L, Parnetti L, Farotti L, Pievani M, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Yener G, Emek-Savaş DD, Triggiani AI, Taylor JP, McKeith I, Stocchi F, Vacca L, Frisoni GB, De Pandis MF.
    Neurobiol Aging; 2019 Jan; 73():9-20. PubMed ID: 30312790
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease.
    Mostile G, Nicoletti A, Dibilio V, Luca A, Pappalardo I, Giuliano L, Cicero CE, Sciacca G, Raciti L, Contrafatto D, Bruno E, Sofia V, Zappia M.
    Parkinsonism Relat Disord; 2015 Aug; 21(8):948-53. PubMed ID: 26096796
    [Abstract] [Full Text] [Related]

  • 6. Levodopa and the feedback process on set-shifting in Parkinson's disease.
    Au WL, Zhou J, Palmes P, Sitoh YY, Tan LC, Rajapakse JC.
    Hum Brain Mapp; 2012 Jan; 33(1):27-39. PubMed ID: 21438075
    [Abstract] [Full Text] [Related]

  • 7. [Dynamics of cognitive impairments during L-dopa therapy in Parkinson's disease].
    Ismailova SB, Prokopenko SV, Pokhabov DV, Mosaleva EI, Alekseenko PV, Zhumzhanov IM.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021 Jan; 121(7):36-41. PubMed ID: 34460155
    [Abstract] [Full Text] [Related]

  • 8. Frontal-subcortical defects correlate with task switching deficits in Parkinson`s disease.
    Gul A, Yousaf J, Ahmad H.
    Neurosciences (Riyadh); 2017 Jul; 22(3):224-227. PubMed ID: 28678219
    [Abstract] [Full Text] [Related]

  • 9. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.
    Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ.
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1323-8. PubMed ID: 16952917
    [Abstract] [Full Text] [Related]

  • 10. The effect of anticholinergic drugs on cognition of patients with Parkinson's disease: a cohort study from the Egyptian population.
    Hamed SA, Hadad AFE.
    Expert Rev Clin Pharmacol; 2024 Aug; 17(8):743-753. PubMed ID: 38781022
    [Abstract] [Full Text] [Related]

  • 11. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group.
    Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH.
    Neurology; 1998 May; 50(5):1327-31. PubMed ID: 9595982
    [Abstract] [Full Text] [Related]

  • 12. Cognitive and cortical thinning patterns of subjective cognitive decline in patients with and without Parkinson's disease.
    Hong JY, Yun HJ, Sunwoo MK, Ham JH, Lee JM, Sohn YH, Lee PH.
    Parkinsonism Relat Disord; 2014 Sep; 20(9):999-1003. PubMed ID: 25001316
    [Abstract] [Full Text] [Related]

  • 13. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
    Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P.
    J Parkinsons Dis; 2018 Sep; 8(1):59-70. PubMed ID: 29480220
    [Abstract] [Full Text] [Related]

  • 14. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M, Klepac N.
    J Neurol Sci; 2006 Oct 25; 248(1-2):251-4. PubMed ID: 16797593
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 25; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 16. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R.
    Neurosci Biobehav Rev; 2006 May 25; 30(1):1-23. PubMed ID: 15935475
    [Abstract] [Full Text] [Related]

  • 17. L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network.
    Jubault T, Monetta L, Strafella AP, Lafontaine AL, Monchi O.
    PLoS One; 2009 Jul 07; 4(7):e6154. PubMed ID: 19584921
    [Abstract] [Full Text] [Related]

  • 18. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
    Kwak Y, Müller ML, Bohnen NI, Dayalu P, Seidler RD.
    Behav Brain Res; 2012 Apr 21; 230(1):116-24. PubMed ID: 22343069
    [Abstract] [Full Text] [Related]

  • 19. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
    Palmer SJ, Eigenraam L, Hoque T, McCaig RG, Troiano A, McKeown MJ.
    Neuroscience; 2009 Jan 23; 158(2):693-704. PubMed ID: 18722512
    [Abstract] [Full Text] [Related]

  • 20. L-Dopa response to Cortical Dysfunctions, health related quality of life and Fatigue Severity in Idiopathic Parkinson's disease.
    Gul A, Yousaf J.
    Pak J Med Sci; 2018 Jan 23; 34(4):1014-1018. PubMed ID: 30190772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.